Status:
NOT_YET_RECRUITING
Role of Uromodulin in Management of Multiple Myloma
Lead Sponsor:
Assiut University
Conditions:
Multiple Myloma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
• To Evaluate the role of uromodulin level in early diagnosis of cast nephropathy and to detect its prognostic value in multiple myeloma patients
Detailed Description
Multiple myeloma (MM) is a malignant plasma cell disorder . It is the second most common hematologic malignancy worldwide . It accounts for 15%-20% of all hematologic malignancies and has a 5-year sur...
Eligibility Criteria
Inclusion
- Adult patients ≥ 18 years old that newly diagnosed with multiple myeloma according to 2024 updates in diagnosis of multiple myeloma (10) with and without renal impairment at nephrology and haematology unit of internal medicine department.
Exclusion
- any patient have evidence of renal impairment due to any cause other than multiple myeloma as diabetic nephropathy, hypertensive nephropathy or lupus nephritis ... etc.
Key Trial Info
Start Date :
March 25 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 25 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06876298
Start Date
March 25 2025
End Date
March 25 2027
Last Update
March 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut University
Asyut, Eygpt, Egypt, 71525